Regeneron Genetics Center Selects Olink® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples
Thermo Fisher Scientific, the world leader in serving science, today announced that the Regeneron Genetics Center ® (RGC™) has selected the Olink Explore HT proteomics platform for a large-scale proteomics investigation involving nearly 200,000 patient samples from the Geisinger Health Study that aims to unlock new insights into the dynamic biology and mechanisms of human disease.
The Geisinger Health Study, characterized by deep phenotyping data, offers a unique opportunity to monitor proteomic changes at scale. RGC's established infrastructure is designed to manage large-scale projects and is built for the efficient execution of this ambitious endeavor. RGC's selection of Olink Explore HT follows the platform's selection for use in the UK Biobank Pharma Proteomics Project (UKB-PPP), the world's largest human proteomics study.
The Geisinger Health Study aims to validate genetic hypotheses, solidify drug targets identified by RGC's world-class genomic sequencing operation, and discover novel disease biomarkers to improve drug development efficiencies. Olink Explore HT was chosen for its unparalleled scalability, high throughput, and superior specificity, all of which are essential for processing such a vast number of samples.
'We are thrilled to partner with RGC on this groundbreaking project,' said Carl Raimond, president, proteomic sciences, Thermo Fisher Scientific. 'The selection of Olink Explore HT underscores its ability to deliver robust and reliable data at scale. This important work will accelerate the pace of biomarker discovery and contribute significantly to the advancement of precision medicine.'
RGC is a cutting-edge research organization focused on uncovering genetic and proteomic insights, ensuring superb data stewardship, and ultimately driving scientific advancements in preventing and treating human disease. The integration of Olink Explore HT into their workflow signifies another major step forward in their commitment to leveraging multi-omics data for improved outcomes.
'The Olink Explore HT platform has proven to be an invaluable tool in our pursuit of deeper biological understanding,' stated John Overton, Vice President at Regeneron Genetics Center. 'Its scalability and specificity are essential for handling the complexities of a project of this size. We believe this ambitious endeavor will yield transformative insights that will drive innovation in scientific discoveries.'
The comprehensive mapping of protein levels across such a large population of patient samples represents a significant milestone in the field of proteomics, paving the way for future studies to advance our understanding of human health and disease.
Learn more about Olink Explore HT .
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612733998/en/
CONTACT: Media Contact:
Michael B. Gonzales, PhD
Thermo Fisher Scientific
E-mail:[email protected]
KEYWORD: EUROPE SWEDEN UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH GENETICS HEALTH TECHNOLOGY CLINICAL TRIALS RESEARCH SCIENCE
SOURCE: Thermo Fisher
Copyright Business Wire 2025.
PUB: 06/12/2025 08:15 AM/DISC: 06/12/2025 08:16 AM
http://www.businesswire.com/news/home/20250612733998/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration ('FDA') for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS (zongertinib tablets), a tyrosine kinase inhibitor (TKI). The HERNEXEOS, developed by Boehringer Ingelheim, is the first and only FDA-approved orally administered targeted therapy for adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). The recent approval is expected to bolster Thermo Fisher's Specialty Diagnostics arm. About TMO's Oncomine Dx Target Test The Oncomine Dx Target Test checks if NSCLC tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations. It enables multi-biomarker analysis from a single tissue sample to aid treatment decisions in as little as four days. This reduces the need for second biopsies and avoids suboptimal therapy selection in the absence of a complete biomarker report. The test is fully reimbursed by Medicare, as well as by the top 20 commercial payers in the United States. Oncomine Dx Target Test's Global Approvals The Oncomine Dx Target Test received its first approval by the FDA as an NGS CDx in 2017, followed by regulatory approvals in 20 countries for 11 biomarkers and over 20 targeted therapies. The test is reimbursed by government and commercial insurers in the United States, Europe, Japan, South Korea and Israel, covering more than 550 million lives globally. In the United States alone, it is approved for targeted therapies in NSCLC, cholangiocarcinoma (CC), astrocytoma (AC) and oligodendroglioma (OG), anaplastic thyroid cancer (ATC), medullary thyroid cancer (MTC) and thyroid cancer (TC). Industry Prospects Favor TMO According to the American Cancer Society, lung cancer is the second most common cancer in both men and women in the United States, with NSCLC accounting for about 85-90% of all lung cancer cases. Research further indicates that roughly 2-4% of NSCLC patients carry a HER2 mutation. With lung cancer cases continuing to rise, the global market for NSCLC treatments is expected to expand significantly, reaching $66.04 billion by 2032 at a CAGR of 10.3% from 2024 to 2032 (per Fortune Business Insights). Another Development by TMO Thermo Fisher recently announced the FDA approval for Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY (sunvozertinib) and in tumor profiling. Offerings by TMO's Competitors In the oncology space, Thermo Fisher faces competition from some prominent MedTech players. These companies are also making notable developments in their respective businesses. An expanding NGS oncology portfolio is helping Illumina ILMN drive the revolution in cancer genomics. The company's market-leading TruSight Oncology assay, TSO 500, continues to see increased utilization and broader adoption. In February, the company announced a new single-cell offering for CRISPR research with applications in oncology, immunology and drug target discovery. In 2024, the FDA approved its in vitro diagnostic (IVD) TSO Comprehensive test and its first two companion diagnostic (CDx) indications to rapidly match patients to targeted therapies. This year, Illumina is set to roll out TSO 500 v2, a new version that includes hundreds of genes across all variant classes and immuno-oncology biomarkers in a single assay from one sample, to facilitate therapy selection research. A rapidly expanding liquid biopsy and NGS-based testing portfolio is positioning Guardant Health GH as a leader in precision oncology. The company's flagship Guardant360 test has been recently enhanced with the Guardant Infinity platform, enabling a single blood draw to provide comprehensive tumor profiling, confirm the absence of actionable mutations and determine ER/PR/HER2 status. Regulatory milestones include approvals for Guardant360 CDx as a companion diagnostic in the United States, Japan and Singapore, covering multiple cancer targets such as EGFR and HER2 mutations. Its pipeline also includes the FDA-approved Shield blood test for colorectal cancer screening, offering a non-invasive alternative to colonoscopy. Exact Sciences' EXAS flagship screening product, the Cologuard test, is a non-invasive, stool-based DNA (sDNA) screening test that utilizes a multitarget approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company's precision oncology portfolio also offers the Oncotype DX Breast Recurrence Score test to identify patients who are most likely to benefit from chemotherapy, as well as those who may receive no clinical benefit from chemotherapy. Its Oncotype DX Colon Recurrence Score test is a multi-gene test for predicting recurrence risk in patients with stage II and stage III A/B colon cancer to enable an individualized approach to treatment planning. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Guardant Health, Inc. (GH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
16 hours ago
- Yahoo
Wells Fargo Reaffirms ‘Buy' Rating on Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher Scientific Inc. (NYSE:TMO) is included in our list of the . A scientist performing a blood test on a patient using life sciences tools & services. Backed by the company's strong momentum across several key business segments, Wells Fargo reaffirmed its 'Buy' rating on Thermo Fisher Scientific Inc. (NYSE:TMO) on July 28, 2025. For Q2 2025, the company recorded strong growth across its Pharma Services, Bioproduction, and the Research/Safety Channel segments. The Research/Safety Channel segment saw TMO outperform its competitors, such as Avantor, with strong market share gains. The analyst acknowledged softness in the Analytical Instruments segment; however, the quarter's overall strong performance fueled optimism. Looking ahead, the analyst believes Thermo Fisher Scientific Inc. (NYSE:TMO)'s diversified portfolio and increasing market share will drive its growth. Thermo Fisher Scientific Inc. (NYSE:TMO) delivers life science solutions, alongside analytical instruments, specialty diagnostics, and laboratory products. It is included in our list of the Best Rebound Stocks To Buy. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best AI Stocks to Buy Under $3 and Bill Ackman Stock Portfolio: Top 10 Stock Picks. Disclosure: None. Sign in to access your portfolio
Business Wire
a day ago
- Business Wire
FUN Investors Have Opportunity to Join Six Flags Entertainment Corporation Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Six Flags Entertainment Corporation ('Six Flags' or 'the Company') (NYSE: FUN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Six Flags announced its Q2 2025 financial results on August 6, 2025. The Company swung from a profit to a $100 million dollar loss for the quarter, and cut its full year guidance. The Company blamed bad weather for the downturn but also indicated lower sales of season passes contributed to poor results. Finally, the Company's CEO will step down at the end of the year. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
